Core Insights - The focus of the call is on the clinical and regulatory aspects of Sanofi's mid- and late-stage pipeline, emphasizing the importance of science and patience over commercial or financial discussions [2] - Key events in 2025 across various therapeutic areas such as immunology, rare diseases, hemato-oncology, neurology, and vaccines will be highlighted, along with news flow items for the first half and second half of next year and into 2027 [3] - There is a noted deflation of expectations for some 2025 news items, leading to a general anticipation of lower news flow for the upcoming year [3] Group 1 - The call is led by Thomas Kudsk Larsen from the Investor Relations team, indicating a structured approach to investor communication [1] - The presentation aims to keep the discussion focused on scientific developments rather than financial performance [2] Group 2 - The company plans to provide a comprehensive overview of its pipeline, which includes significant therapeutic areas and timelines for upcoming news [3] - The emphasis on lower anticipation for next year's news flow suggests a strategic adjustment in expectations for stakeholders [3]